

Full protection of swine against foot-and-mouth disease by a bivalent B-cell epitope dendrimer peptide vaccine

Esther Blanco David Andreu

Rodrigo Cañas
Patricia de León
M. Jose Bustos
Elisa Torres
Miguel Rodríguez-Pulido
Marga Sáiz

Conventional FMD vaccines

CONVENTIONAL VACCINES (chemically inactivated viruses)


- + Good protection against antigenically related viruses.
- Its use is instrumental for disease control
- *Risk of viral escapes from vaccine production plants*
- *A cold-chain is required*
- *Need for differentiation between infected and vaccinated animals*
- *Antigenic match between field viruses and vaccine strains*



“Vaccination to live”: recently gained acceptance

- World Organization for Animal Health (OIE) Code:
 - recognized a new category “FMD-free country/zone where vaccination is practised”.
 - Reduced the waiting periods to recover the status when vaccination is applied during emergencies.
- Vaccination minimizes the dependence on large-scale culling of animals to control the disease.

Peptide-based vaccines




pros 👍

- No infectious agent involved
- High structural flexibility. Easily adaptable to new, different strains
- Combination of B and T cell epitopes
- Total differentiation between infected and vaccinated animals (DIVA)
- Safe storage and transport (no cold-chain required)
- Fast, affordable large scale production

cons 🙋

- Most epitopes are conformational (discontinuous)
- conformational epitopes difficult to reproduce by chemical means
- immunogenicity usually needs to be enhanced by:
adjuvants
multimerization


VP1 GH loop: a B cell antigenic site in FMDV capsid used for peptide vaccines design



VP1 GH loop
(site A)



A continuous B cell site that can be mimicked using synthetic peptides




Integrin-Binding
Motif (RGD)

*Highly variable in sequence:
serotype specific*

Limited immunogenicity of
GH loop linear peptides



An improved synthetic peptide vaccine: pig as a model



Multivalent, dendrimeric scaffolds (dendrimers)


Esther Blanco et al. J. Virol (2000)
Esther Blanco et al. J. Virol (2001)
Mercedes García-Briones et al. Virology (2004)

The dendrimeric peptide of type C FMDV

Peptide	FMDV protein residues	Sequence
B	VP1 [136-154]	YTASARGDLAHLTTTHARH-amide
T	3A [21-35]	AAIEFFEGMVHDSIK-amide
B₄T*	VP1 [136-154] 3A [21-35]	<p>YTASARGDLAHLTTTHARH-C YTASARGDLAHLTTTHARH-C YTASARGDLAHLTTTHARH-C YTASARGDLAHLTTTHARH-C</p> <p>CH₂CO-S-CH₂CO-K K-KK-AAIEFFEGMVHDSIK-amide</p>

* Thioether linkage(C-terminal)

Arrow indicates a putative cathepsin D cleavage site



Solid, Sterilizing Protection


Neutralizing Ab

Specific IgA in serum and mucosae

FMDV-specific T cell responses

Peptides as vaccines against foot-and-mouth disease virus

Extension to other FMDVs epidemiologically relevant: type O (O UK 2001)



Dissecting the B₄T components responsible for the immunity observed: Improved, cost- effective dendrimeric constructions

- Mouse (screening model)
- Swine




Patents P20130101063, P20130101063, 2013800289123



Swiss mice "outbred"
(100 µg peptide/mouse)

Is tetra- or bivalentency essential? B₄T vs. B₂T constructs (O UK 2001)

B epitope: VP1 140-160
T epitope: 3A 21-35





Esther Blanco et al. Clin. Dev. Immunol. (2013)



Swiss mice

2. Orientation and attachment mode also matter!




A

- 1 C-terminal attachment
- ◇- 2 N-terminal attachment
- 3 "Reverse" thioether attachment
- ▲- 4 Maleimide attachment

Peptide

Ease of production
Lower cost





Maleimide attachment Chem. (2013)



Protection conferred in pigs by type O tetra - and bivalent dendrimers (O UK 2001)



2 mg peptide/ 2 doses
Montanide ISA 50V2
(commercial oil adjuvant)




Total and neutralizing Ab elicited by type O tetra - and bivalent dendrimers



Bivalent dendrimers elicit higher levels of IFN γ -producing activated T cells


ELISPOT IFN γ




Esther Blanco et al., et al. Antiviral Res. (2016)

Bivalent dendrimer B₂T (mal) elicits long lasting neutralizing antibodies associated with the induction of IFN γ -producing T cells

VNT




ELISPOT IFN γ







Dendrimers can afford solid FMD protection: ongoing work with this modular approach

- Optimizing conjugation chemistry and inclusion of new T cell epitopes taking advantage of the versatility of the dendrimeric modular approach.
- Incorporation of different B cell peptide sequences in single dendrimers/combination of different dendrimeric molecules



Isotypes of the Ab elicited by type O tetra - and bivalent dendrimers



- This results suggests association between a Th-1 biased isotype balance (lower IgG1/IgG2 ratio) and improved protection
- IgG2 and IgA can enhance T cell responses via an FcR-mediated mechanism